Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30165832 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KDM4EPKMMAPTTDP1 | |
| SCHEMBL7230204 | 0.81 | ADRB1 (0.44) | ALDH1A1CYP2D6KDM4EPKMMAPT | |
| SCHEMBL7258863 | 0.78 | ADRB1 (0.44) | ALDH1A1KDM4EMAPTTDP1 | |
| SCHEMBL14461955 | 0.77 | KMT2A (0.44) | ALDH1A1PKMMAPT | |
| SCHEMBL25255721 | 0.77 | CYP1A2 (0.46) | CYP1A2CYP2D6FAAHMGLLPKM | |
| SCHEMBL29068350 | 0.76 | CYP1A2 (0.57) | ALDH1A1CYP1A2CYP2D6FAAHMGLL | |
| SCHEMBL28408131 | 0.75 | ADRB1 (0.43) | ALDH1A1KDM4EMAPTTDP1 | |
| SCHEMBL16261916 | 0.74 | DPP4 (0.41) | KDM4EMAPT | |
| SCHEMBL8498489 | 0.72 | DPP4 (0.41) | CYP2D6 | |
| SCHEMBL1333584 | 0.72 | CYP1A2 (0.61) | ALDH1A1CYP1A2CYP2D6FAAHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110046135-A1 | NEW COMPOUNDS I | ASTRAZENECA AB (PUBL) (SE) | 2011-02-24 | — | — | US | disclosed |
| US-7851471-B2 | Compounds I | ASTRAZENECA AB (PUBL) (SE) | 2010-12-14 | — | — | US | disclosed |
| EP-2229362-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | AstraZeneca AB (SE) | 2010-09-22 | — | — | EP | disclosed |
| US-20090181967-A1 | New compounds I | BIOVITRUM AB (SE) | 2009-07-16 | — | — | US | disclosed |
| WO-2009071658-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181967-A1 | New compounds I | GPR119, GLP1R, FABP4 | ALDH1A1 2089/4885CYP1A2 1922/4885CYP2D6 3403/4885 |
| US-20110046135-A1 | NEW COMPOUNDS I | GPR119, GLP1R, FABP4 | ALDH1A1 2089/4885CYP1A2 1922/4885CYP2D6 3403/4885 |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | GPR119, FABP4, ADIPOR2 | ALDH1A1 1389/4885CYP1A2 1352/4885CYP2D6 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.